α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
HCC
alpha-fetoprotein
atezolizumab plus bevacizumab
eosinophils
lenvatinib
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
23 Nov 2023
23 Nov 2023
Historique:
revised:
02
10
2023
received:
27
07
2023
accepted:
31
10
2023
medline:
23
11
2023
pubmed:
23
11
2023
entrez:
23
11
2023
Statut:
aheadofprint
Résumé
Atezolizumab plus bevacizumab (AB) and lenvatinib can be alternatively used as first-line systemic treatment of unresectable hepatocellular carcinoma (HCC). However, no direct comparison of the two regimens has been performed in randomized clinical trials, making the identification of baseline differential predictors of response of major relevance to tailor the best therapeutic option to each patient. Baseline clinical and laboratory characteristics of real-world AB-treated HCC patients were analyzed in uni- and multivariate analyses to find potential prognostic factors of overall survival (OS). Significant variables were incorporated in a composite score (α-FAtE) and it was tested for specificity and sensitivity in receiver operating characteristic (ROC) curve and in multivariate analysis for OS. The score was applied in uni- and multivariate analyses for OS of a comparable lenvatinib-treated HCC population. Finally, comparison between treatments was performed in patients with low and high α-FAtE scores and predictivity estimated by interaction analysis. Time-to-progression (TTP) was a secondary endpoint. OS of AB-treated HCC patients was statistically longer in those with α-fetoprotein <400 ng/mL (HR 0.62, p = .0407), alkaline phosphatase (ALP) <125 IU/L (HR 0.52, p = .0189) and eosinophil count ≥70/μL (HR 0.46, p = .0013). The α-FAtE score was generated by the sum of single points attributed to each variable among the above reported. In ROC curve analysis, superior sensitivity and specificity were achieved by the score compared to individual variables (AUC 0.794, p < .02). Patients with high score had longer OS (HR 0.44, p = .0009) and TTP (HR 0.34, p < .0001) compared to low score if treated with AB, but not with lenvatinib. Overall, AB was superior to lenvatinib in high score patients (HR 0.55, p = .0043) and inferior in low score ones (HR 1.75, p = .0227). At interaction test, low α-FAtE score resulted as negative predictive factor of response to AB (p = .0004). In conclusion, α-FAtE is a novel prognostic and predictive score of response to first-line AB for HCC patients that, if validated in prospective studies, could drive therapeutic choice between lenvatinib and AB.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 UICC.
Références
da Fonseca LG, Reig M, Bruix J. Tyrosine kinase inhibitors and hepatocellular carcinoma. Clin Liver Dis. 2020;24:719-737. doi:10.1016/j.cld.2020.07.012
Fang P, Hu J, Cheng Z, Liu Z, Wang J, Jiao S. Efficacy and safety of bevacizumab for the treatment of advanced hepatocellular carcinoma: a systematic review of phase II trials. PloS One. 2012;7:e49717. doi:10.1371/journal.pone.0049717
Zhu AX, Kang Y-K, Yen C-J, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:282-296. doi:10.1016/S1470-2045(18)30937-9
Sangro B, Sarobe P, Hervás-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18:525-543. doi:10.1038/s41575-021-00438-0
Chan L-K, Tsui Y-M, Ho DW-H, Ng IO-L. Cellular heterogeneity and plasticity in liver cancer. Semin Cancer Biol. 2022;82:134-149. doi:10.1016/j.semcancer.2021.02.015
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390. doi:10.1056/NEJMoa0708857
Cheng A-L, Kang Y-K, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34. doi:10.1016/S1470-2045(08)70285-7
Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163-1173. doi:10.1016/S0140-6736(18)30207-1
Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894-1905. doi:10.1056/NEJMoa1915745
Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1. doi:10.1056/EVIDoa2100070
Vogel A, Rimassa L, Sun H-C, et al. Comparative efficacy of atezolizumab plus bevacizumab and other treatment options for patients with unresectable hepatocellular carcinoma: a network meta-analysis. Liver Cancer. 2021;10:240-248. doi:10.1159/000515302
Casadei-Gardini A, Tada T, Shimose S, et al. Is atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma superior even to lenvatinib? A matching-adjusted indirect comparison. Target Oncol. 2021;16:249-254. doi:10.1007/s11523-021-00803-8
Kim BK, Cheon J, Kim H, et al. Atezolizumab/bevacizumab vs. lenvatinib as first-line therapy for unresectable hepatocellular carcinoma: a real-world, multi-center study. Cancers (Basel). 2022;14:1747. doi:10.3390/cancers14071747
Rimini M, Rimassa L, Ueshima K, et al. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis. ESMO Open. 2022;7:100591. doi:10.1016/j.esmoop.2022.100591
Casadei-Gardini A, Rimini M, Tada T, et al. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. Eur J Cancer. 2023;180:9-20. doi:10.1016/j.ejca.2022.11.017
Fransvea E, Paradiso A, Antonaci S, Giannelli G. HCC heterogeneity: molecular pathogenesis and clinical implications. Cell Oncol. 2009;31:227-233. doi:10.3233/CLO-2009-0473
Ayuso C, Rimola J, Vilana R, et al. Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. Eur J Radiol. 2018;101:72-81. doi:10.1016/j.ejrad.2018.01.025
Carr BI, Guerra V, Donghia R, Yilmaz S. Tumor multifocality and serum albumin levels can identify groups of patients with hepatocellular carcinoma and portal vein thrombosis having distinct survival outcomes. Ann Med Surg. 2021;66. doi:10.1016/j.amsu.2021.102458
Kariyama K, Hiraoka A, Kumada T, et al. Chronological change in serum albumin as a prognostic factor in patients with hepatocellular carcinoma treated with lenvatinib: proposal of albumin simplified grading based on the modified albumin-bilirubin score (ALBS grade). J Gastroenterol. 2022;57:581-586. doi:10.1007/s00535-022-01883-7
Fu X, Yang Y, Zhang D. Molecular mechanism of albumin in suppressing invasion and metastasis of hepatocellular carcinoma. Liver Int. 2022;42:696-709. doi:10.1111/liv.15115
Zhu AX, Dayyani F, Yen C-J, et al. Alpha-fetoprotein as a potential surrogate biomarker for atezolizumab + bevacizumab treatment of hepatocellular carcinoma. Clin Cancer Res. 2022;28:3537-3545. doi:10.1158/1078-0432.CCR-21-3275
Kelley RK, Meyer T, Rimassa L, et al. Serum alpha-fetoprotein levels and clinical outcomes in the phase III CELESTIAL study of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2020;26:4795-4804. doi:10.1158/1078-0432.CCR-19-3884
Zhu AX, Finn RS, Kang Y-K, et al. Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. Br J Cancer. 2021;124:1388-1397. doi:10.1038/s41416-021-01260-w
Pfister D, Núñez NG, Pinyol R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592:450-456. doi:10.1038/s41586-021-03362-0
Pinyol R, Torrecilla S, Wang H, et al. Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol. 2021;75:865-878. doi:10.1016/j.jhep.2021.04.049
Huby T, Gautier EL. Immune cell-mediated features of non-alcoholic steatohepatitis. Nat Rev Immunol. 2022;22:429-443. doi:10.1038/s41577-021-00639-3
Zhang Q, Liu H, Wang H, et al. Lenvatinib promotes antitumor immunity by enhancing the tumor infiltration and activation of NK cells. Am J Cancer Res. 2019;9:1382-1395.
Galle PR, Foerster F, Kudo M, et al. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int. 2019;39:2214-2229. doi:10.1111/liv.14223
Kim JM, Kwon CHD, Joh J-W, et al. The effect of alkaline phosphatase and intrahepatic metastases in large hepatocellular carcinoma. World J Surg Oncol. 2013;11:40. doi:10.1186/1477-7819-11-40
Huang C-W, Wu T-H, Hsu H-Y, et al. Reappraisal of the role of alkaline phosphatase in hepatocellular carcinoma. J Pers Med. 2022;12:518. doi:10.3390/jpm12040518
Zhang X, Xin Y, Chen Y, Zhou X. Prognostic effect of albumin-to-alkaline phosphatase ratio on patients with hepatocellular carcinoma: a systematic review and meta-analysis. Sci Rep. 2023;13:1808. doi:10.1038/s41598-023-28889-2
Grisaru-Tal S, Rothenberg ME, Munitz A. Eosinophil-lymphocyte interactions in the tumor microenvironment and cancer immunotherapy. Nat Immunol. 2022;23:1309-1316. doi:10.1038/s41590-022-01291-2
Lucarini V, Ziccheddu G, Macchia I, et al. IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils. Onco Targets Ther. 2017;6:e1317420. doi:10.1080/2162402X.2017.1317420
Jacquelot N, Seillet C, Wang M, et al. Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma. Nat Immunol. 2021;22:851-864. doi:10.1038/s41590-021-00943-z
Pesce S, Thoren FB, Cantoni C, et al. The innate immune cross talk between NK cells and eosinophils is regulated by the interaction of natural cytotoxicity receptors with eosinophil surface ligands. Front Immunol. 2017;8. doi:10.3389/fimmu.2017.00510
Qi L, Zhang Q, Miao Y, et al. Interleukin-33 activates and recruits natural killer cells to inhibit pulmonary metastatic cancer development. Int J Cancer. 2020;146:1421-1434. doi:10.1002/ijc.32779
O'Flaherty SM, Sutummaporn K, Häggtoft WL, et al. TLR-stimulated eosinophils mediate recruitment and activation of NK cells in vivo. Scand J Immunol. 2017;85:417-424. doi:10.1111/sji.12554
Reichman H, Itan M, Rozenberg P, et al. Activated eosinophils exert antitumorigenic activities in colorectal cancer. Cancer Immunol Res. 2019;7:388-400. doi:10.1158/2326-6066.CIR-18-0494
Alves A, Dias M, Campainha S, Barroso A. Peripheral blood eosinophilia may be a prognostic biomarker in non-small cell lung cancer patients treated with immunotherapy. J Thorac Dis. 2021;13:2716-2727. doi:10.21037/jtd-20-3525
Herrmann T, Ginzac A, Molnar I, Bailly S, Durando X, Mahammedi H. Eosinophil counts as a relevant prognostic marker for response to nivolumab in the management of renal cell carcinoma: a retrospective study. Cancer Med. 2021;10:6705-6713. doi:10.1002/cam4.4208
Moreira A, Leisgang W, Schuler G, Heinzerling L. Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy. Immunotherapy. 2017;9:115-121. doi:10.2217/imt-2016-0138
Nishikawa D, Suzuki H, Beppu S, et al. Eosinophil prognostic scores for patients with head and neck squamous cell carcinoma treated with nivolumab. Cancer Sci. 2021;112:339-346. doi:10.1111/cas.14706
Hude I, Sasse S, Bröckelmann PJ, et al. Leucocyte and eosinophil counts predict progression-free survival in relapsed or refractory classical Hodgkin lymphoma patients treated with PD1 inhibition. Br J Haematol. 2018;181:837-840. doi:10.1111/bjh.14705
Orsi G, Tovoli F, Dadduzio V, et al. Prognostic role of blood eosinophil count in patients with sorafenib-treated hepatocellular carcinoma. Target Oncol. 2020;15:773-785. doi:10.1007/s11523-020-00757-3
Okamoto K, Ikemori-Kawada M, Jestel A, et al. Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization. ACS Med Chem Lett. 2015;6:89-94. doi:10.1021/ml500394m